{'fraction_non_alphanumeric': 0.032667876588021776, 'fraction_numerical': 0.0, 'mean_word_length': 5.202247191011236, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
How many people develop anti‐drug antibodies to the biologic drug tildrakizumab, and what impact does this have on the effectiveness of their treatment

Biologics are powerful drugs used to treat a range of diseases including psoriasis. They can be very effective; however, the body's immune system, which normally fights off infection, can produce ‘anti‐drug antibodies’ (or ADAs) that see biologics as harmful ‘invaders’ and try to deactivate them. These antibodies may result in serious side effects and/or may reduce the effectiveness of the drug.